Evicenter
MarkdownMedical informationP&T meetings
Vonaprument (ANX007)

Geographic atrophy secondary to age-related macular degeneration

Launch
Not announced
Last updated
167 sources

Clinical evidence

ARCHER II

59 evidence topics · 20 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using confirmed best-corrected visual acuity loss of 15 or more ETDRS letters as the primary endpoint
Functional primary endpoints of approved retinal products
Statistical analysis description
Number of participants (Planned and analyzed)
Number analyzed

No evidence found.

Description of analysis sets
Definitions of efficacy and safety analysis populations

No evidence found.

Results
Participant disposition
Disposition by treatment arm

No evidence found.

Baseline characteristics
Demographic and structural characteristics compared with ARCHER
CharacteristicARCHER (N = 270)ARCHER II (N = 659)
Age, mean (SD)“80.0 (8.2)”“78.4 (8.0)”
Female“61.5%”“63.0%”
GA lesion size (mm2), mean (SD)“7.36 (4.01)”“7.23 (3.49)”
GA lesion location, subfoveal“51.9%”“54.8%”
Total EZ loss, mm2 (% of total area lost)“12.7 (35.3%)”“12.3 (34.3%)”
Visual acuity characteristics compared with ARCHER
CharacteristicARCHER (N = 270)ARCHER II (N = 659)
Mean BCVA (SD), letters“58.4 (16.2)”“65.8 (10.5)”
Baseline BCVA below 45 letters“23.3%”“0.0%”
Mean LLVA (SD), letters“33.0 (16.9)”“38.3 (17.2)”
Mean LLVD (SD), letters“25.7 (16.9)”“27.6 (15.6)”
LLVD below 30 letters“62.4%”“60.7%”
Baseline characteristics by treatment arm

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: design features and absence of results

As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.

The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.

For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.